| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Furusyo N et al. | Rapidly growing primary gastric B-cell lymphoma after eradication of Helicobacter pylori. | 1999 | Intern. Med. | pmid:10526942 |
| Chérin P et al. | Macrophagic myofasciitis: improvement with antibiotic therapy. | 1999 | J. Rheumatol. | pmid:10529163 |
| Moola S et al. | A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. | 1999 | Chest | pmid:10531162 |
| Gonzalez Cueto D et al. | [Gastric solitary plasmacytoma associated with +Helicobacter pylori infection]. | 1999 | Acta Gastroenterol. Latinoam. | pmid:10533659 |
| Saito H et al. | [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice]. | 1999 | Kekkaku | pmid:10535281 |
| Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
| Hammett DC and Evans MF | Functional (non-ulcer) dyspepsia and Helicobacter pylori infection. To treat or not to treat? | 1999 | Can Fam Physician | pmid:10540692 |
| Sassa K et al. | Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. | 1999 | Antimicrob. Agents Chemother. | pmid:10543765 |
| Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
| Unal M et al. | Ocular toxicity of intravitreal clarithromycin. | 1999 | Retina (Philadelphia, Pa.) | pmid:10546942 |
| Woo PC et al. | Antibiotics modulate vaccine-induced humoral immune response. | 1999 | Clin. Diagn. Lab. Immunol. | pmid:10548572 |
| Adamsson I et al. | Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. | 1999 | J. Antimicrob. Chemother. | pmid:10552979 |
| Cirioni O et al. | In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. | 1999 | J. Antimicrob. Chemother. | pmid:10552982 |
| Yoshida Y et al. | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10560737 |
| Valencia IC et al. | Disseminated cutaneous Mycobacterium chelonae infection after injection of bovine embryonic cells. | 1999 | Int. J. Dermatol. | pmid:10561050 |
| MartÃn de Argila C and Boixeda D | [A ration proposal for the eradicating treatment of Helicobacter pylori infection]. | 1999 | Med Clin (Barc) | pmid:10562929 |
| Adeyemi EO et al. | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. | 1999 | Eur J Gastroenterol Hepatol | pmid:10563537 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Fattorini L et al. | Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice. | 1999 | Microb. Drug Resist. | pmid:10566874 |
| Lamouliatte H et al. | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10571611 |
| Stengel W | [Sporotrichoid mycobacteriosis caused by Mycobacterium marinum]. | 1999 | Dtsch. Med. Wochenschr. | pmid:10572519 |
| Madsen LG et al. | Ménétrier's disease and Helicobacter pylori: normalization of gastrointestinal protein loss after eradication therapy. | 1999 | Dig. Dis. Sci. | pmid:10573379 |
| Mach T and Zahradnik-Bilska J | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. | 1999 | Prz. Lek. | pmid:10575912 |
| Dionisio D et al. | Encephalitis caused directly by Mycoplasma pneumoniae. | 1999 | Scand. J. Infect. Dis. | pmid:10576133 |
| Huchon G | How to manage the low-risk patient with lower respiratory tract infection? | 1999 | Respiration | pmid:10577170 |
| de Luis DA et al. | Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. | 1999 | Clin Nutr | pmid:10578022 |
| Tanigawara Y et al. | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. | 1999 | Clin. Pharmacol. Ther. | pmid:10579481 |
| Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
| Komatsu H et al. | Mycobacterium avium infection of the skin associated with lichen scrofulosorum: report of three cases. | 1999 | Br. J. Dermatol. | pmid:10583068 |
| Semret M et al. | Mycobacterium ulcerans infection (Buruli ulcer): first reported case in a traveler. | 1999 | Am. J. Trop. Med. Hyg. | pmid:10586895 |
| Nasu T et al. | [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains]. | 1999 | Jpn J Antibiot | pmid:10587879 |
| Langan CE et al. | Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. | 1999 | J. Antimicrob. Chemother. | pmid:10588313 |
| Rodvold KA | Clinical pharmacokinetics of clarithromycin. | 1999 | Clin Pharmacokinet | pmid:10589373 |
| Franzin L et al. | Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy. | 2000 | Curr. Microbiol. | pmid:10594221 |
| Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
| Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
| Gomollón F et al. | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. | 1999 | Helicobacter | pmid:10597390 |
| Uygun A et al. | The effect of Helicobacter pylori eradication on duodenal gastric metaplasia. | 1999 Jul-Aug | J. Int. Med. Res. | pmid:10599027 |
| Auclair B et al. | Potential interaction between itraconazole and clarithromycin. | 1999 | Pharmacotherapy | pmid:10600094 |
| Feldman M et al. | Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. | 1999 | Am. J. Physiol. | pmid:10600812 |
| Raderer M et al. | Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. | 2000 | Gut | pmid:10601069 |
| Sainz R et al. | [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. | 1999 | Rev Esp Enferm Dig | pmid:10601771 |
| Tanaka G et al. | Effect of clarithromycin on Pseudomonas aeruginosa biofilms. | 2000 Jan-Feb | Chemotherapy | pmid:10601796 |
| Hamada K et al. | Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. | 2000 Jan-Feb | Chemotherapy | pmid:10601798 |
| Fernández-Roblas R et al. | In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10602744 |
| Ku YY et al. | Synthesis and antibacterial activities of novel 12-O-methylerythromycin A derivatives. | 1999 | J. Antibiot. | pmid:10604761 |
| Ianaro A et al. | Anti-inflammatory activity of macrolide antibiotics. | 2000 | J. Pharmacol. Exp. Ther. | pmid:10604943 |
| Suzuki K et al. | Effect of proton pump inhibitor alone or in combination with clarithromycin on mycobacterial growth in human alveolar macrophages. | 2000 | FEMS Microbiol. Lett. | pmid:10612733 |
| Giacometti A et al. | In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614961 |
| Midolo PD et al. | In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614963 |
| Abe S et al. | Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. | 2000 | Am. J. Respir. Cell Mol. Biol. | pmid:10615065 |
| Kiyota K et al. | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. | 1999 | J. Gastroenterol. | pmid:10616771 |
| Aoyama N et al. | Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. | 1999 | J. Gastroenterol. | pmid:10616772 |
| Gotoda T et al. | Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori. | 1999 | J. Gastroenterol. | pmid:10616774 |
| Maeda S et al. | Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. | 2000 | J. Clin. Microbiol. | pmid:10618089 |
| Rocha RT et al. | Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections. | 1999 | Int. J. Clin. Pract. | pmid:10622070 |
| Lugannani C and Strickland C | Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients? | 1999 | J Fam Pract | pmid:10628582 |
| Bui KQ et al. | In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. | 2000 | J. Antimicrob. Chemother. | pmid:10629013 |
| Blondon H | [Eradication of Helicobacter pylori: what is the effect on symptoms of non-ulcerous dyspepsia?]. | 1999 | Presse Med | pmid:10629694 |
| Cammarota G et al. | Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. | 1999 | Dig. Dis. Sci. | pmid:10630486 |
| Bortolotti M et al. | Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1999 | Dig. Dis. Sci. | pmid:10630494 |
| Burgess DS et al. | A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. | 1999 | Ann Pharmacother | pmid:10630825 |
| Juurlink DN and Ito S | Comment: clarithromycin-digoxin interaction. | 1999 | Ann Pharmacother | pmid:10630847 |
| Hoshiya S et al. | Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. | 2000 | J. Gastroenterol. | pmid:10632534 |
| Fujioka T | Clarithromycin resistance in Helicobacter pylori: implications for therapy. | 2000 | J. Gastroenterol. | pmid:10632546 |
| Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
| Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
| Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
| Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
| Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Keiser P et al. | A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection. | 1999 | Int J STD AIDS | pmid:10639059 |
| Miyanohara T et al. | Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. | 2000 | Laryngoscope | pmid:10646728 |
| Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
| Wong BC et al. | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651663 |
| Fock KM et al. | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651664 |
| Chiba N and Marshall CP | Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. | 2000 | Can. J. Gastroenterol. | pmid:10655024 |
| Alarcón T et al. | PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. | 2000 | J. Clin. Microbiol. | pmid:10655418 |
| Allevi P et al. | A new convenient transformation of erythromycin A into clarithromycin. | 1999 | Bioorg. Med. Chem. | pmid:10658579 |
| Yatsunami J et al. | Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. | 1999 | Cancer Lett. | pmid:10660084 |
| Hoshi T et al. | Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori--a comparison before and after H pylori eradication in non-atrophic gastritis. | 1999 | Hum. Pathol. | pmid:10667417 |
| Mordi MN et al. | Acid-catalyzed degradation of clarithromycin and erythromycin B: a comparative study using NMR spectroscopy. | 2000 | J. Med. Chem. | pmid:10669574 |
| Griffith DE et al. | Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. | 2000 | Clin. Infect. Dis. | pmid:10671330 |
| Miyabayashi H et al. | Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori. | 2000 | Helicobacter | pmid:10672049 |
| Dammann HG et al. | Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. | 2000 | Helicobacter | pmid:10672051 |
| Calvet X et al. | Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study. | 2000 | Helicobacter | pmid:10672052 |
| Sevin E et al. | [Helicobacter pylori: identification and detection of clarithromycin resistance by gene amplification]. | 2000 Jan-Feb | Ann. Biol. Clin. (Paris) | pmid:10673617 |
| Kohri K et al. | Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. | 2000 | Eur. Respir. J. | pmid:10678622 |
| Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
| Suleymanlar I et al. | Response to triple treatment with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori infections in continuous ambulatory peritoneal dialysis patients. | 1999 | Adv Perit Dial | pmid:10682076 |
| Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
| Gotfried MH | Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. | 2000 | Clin Ther | pmid:10688386 |
| Bayerdörffer E | [The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol]. | 2000 | Z Gastroenterol | pmid:10689750 |
| Szlachcic A et al. | Helicobacter pylori and its eradication in rosacea. | 1999 | J. Physiol. Pharmacol. | pmid:10695558 |
| Georgopoulos SD et al. | Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. | 2000 | Dig. Dis. Sci. | pmid:10695615 |
| Dore MP et al. | Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. | 2000 | Dig. Dis. Sci. | pmid:10695616 |
| Miwa H et al. | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. | 2000 | Dig. Dis. Sci. | pmid:10695617 |
| Shamaly H et al. | Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis. | 2000 | J. Pediatr. Gastroenterol. Nutr. | pmid:10697140 |
| Ives TJ et al. | In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected vero cell monolayers. | 2000 | J. Antimicrob. Chemother. | pmid:10702548 |
| Schweeger I et al. | Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. | 2000 | Thromb. Res. | pmid:10704650 |